Journal Specialty Index  

Endocrinology, Diabetes & Metabolism

Topic	Issue
Addressing Cardiorenal and Metabolic Protection in Pharmacological Treatment for Type 2 Diabetes: A Complication-Centric Approach	DECEMBER 2025 (II) • VOL. 17 • NO. 13
Radiofrequency Ablation for Thyroid Nodules: Navigating Truths and Myths	DECEMBER 2025 (II) • VOL. 17 • NO. 13
Treat-to-Target in Osteoporosis Management	DECEMBER 2025 (II) • VOL. 17 • NO. 13
Updates in Diagnosing Obesity – a Review of the Lancet Commissioned Paper and Its Impact on Clinical Practice	JUNE 2025 • VOL. 17 • NO. 4
Weight Stigma – an Issue Health Professionals Shouldn’t Ignore	JUNE 2025 • VOL. 17 • NO. 4
"It Takes a Village to Raise a Healthy Child": Management of Paediatric Obesity	JUNE 2025 • VOL. 17 • NO. 4
HKOS Educates Communities on Fighting Obesity	JUNE 2025 • VOL. 17 • NO. 4
Metabolic Effects and Hormonal Alterations in Metabolic and Bariatric Surgery	JUNE 2025 • VOL. 17 • NO. 4
GLP-1 in Obesity and Heart Failure	FEBRUARY 2025 • VOL. 17 • NO. 1
Semaglutide and Tirzepatide for Heart Failure With Preserved Ejection Fraction and Obesity	FEBRUARY 2025 • VOL. 17 • NO. 1
Prevention and Updated Management for Diabetic Kidney Disease	AUGUST 2024 ‧ VOL. 16 ‧ NO. 8
Stratification of the Thyroid Nodule With Ultrasound Examination	AUGUST 2024 ‧ VOL. 16 ‧ NO. 8
Understanding the Diagnosis of Polycystic Ovarian Syndrome	AUGUST 2024 ‧ VOL. 16 ‧ NO. 8
Recent Advances in Nuclear Imaging with Improved Diagnostic Accuracy for Common Endocrine Disorders	AUGUST 2024 ‧ VOL. 16 ‧ NO. 8
Incretin-Based Therapy in Obesity	JANUARY 2024 ‧ VOL. 16 ‧ NO. 1
Lowered BMI Criteria for Metabolic Bariatric Surgery	JANUARY 2024 ‧ VOL. 16 ‧ NO. 1
Renal Health and Obesity	JANUARY 2024 ‧ VOL. 16 ‧ NO. 1
Update in the Management of Fatty Liver	JANUARY 2024 ‧ VOL. 16 ‧ NO. 1
Diabetes in Pregnancy	JULY 2023 ‧ VOL. 15 ‧ NO. 5
Using Neuro-Linguistic Programming Techniques to Facilitate Dietary Habits Change	JULY 2023 ‧ VOL. 15 ‧ NO. 5
Evolution of Management of Papillary Thyroid Microcarcinoma: From Resection to No Resection and Partial Resection	JULY 2023 ‧ VOL. 15 ‧ NO. 5
Cardiometabolic Risks of the Sugar Substitute Erythritol	JULY 2023 ‧ VOL. 15 ‧ NO. 5
SGLT2 Inhibitors: Latest Update	JULY 2023 ‧ VOL. 15 ‧ NO. 5
Diabetes and Cardiology - A Concise and Comprehensive 2022 Update for Frontline Family Doctors	JULY 2022 ‧ VOL. 14 ‧ NO. 6
Update on Glucagon-like Peptide 1 Receptor Agonists	JULY 2022 ‧ VOL. 14 ‧ NO. 6
Thyrotoxicosis Diagnosis/Treatment FAQs	JULY 2022 ‧ VOL. 14 ‧ NO. 6
Management of Adrenal Incidentaloma: Initial Workup and Follow Up	JULY 2022 ‧ VOL. 14 ‧ NO. 6
Practical Guidance From EAS for Combination Lipid-Modifying Therapy in High-and Very-High-Risk Patients	MAY 2022 ‧ VOL. 14 ‧ NO. 4
Advances in LDL-C Management: What's Next?	MAY 2022 ‧ VOL. 14 ‧ NO. 4
Update on Obesity Medications in 2021/2022	JANUARY 2022 ‧ VOL. 14 ‧ NO. 1
New Challenges for Patients Undergoing Bariatric Surgery in the Time of COVID-19	JANUARY 2022 ‧ VOL. 14 ‧ NO. 1
How to Maintain Exercise Levels During the COVID-19 Pandemic	JANUARY 2022 ‧ VOL. 14 ‧ NO. 1
Review of Antihyperglycaemic Agents and Updates for 2021	APRIL 2021 ‧ VOL. 13 ‧ NO. 4
Primary Hyperparathyroidism - An Overlooked Disease	APRIL 2021 ‧ VOL. 13 ‧ NO. 4
Oral Contraceptives, Hormone Replacement Therapy and Breast Cancer Risk	APRIL 2021 ‧ VOL. 13 ‧ NO. 4
Metabolic Diseases in People Living With HIV	DECEMBER 2020 ‧ VOL. 12 ‧ NO. 10
Obesity and Dyslipidaemia	AUGUST 2020 ‧ VOL. 12 ‧ NO. 7
COVID-19 & Obesity - At the Intersection of a Pandemic and an Epidemic	AUGUST 2020 ‧ VOL. 12 ‧ NO. 7
Kidney Disorders and Renoprotection in Obese Patients	AUGUST 2020 ‧ VOL. 12 ‧ NO. 7
Combating Obesity Through Physical Activity	AUGUST 2020 ‧ VOL. 12 ‧ NO. 7
Recent Advances in Diabetes Technology: Continuous Glucose Monitoring Systems	APRIL 2020 ‧ VOL. 12 ‧ NO. 4
Diabetes Foot Disease and Management	APRIL 2020 ‧ VOL. 12 ‧ NO. 4
Current Evidence on the Role of Surgery in the Management of Graves' Disease	APRIL 2020 ‧ VOL. 12 ‧ NO. 4
Use of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure	APRIL 2020 ‧ VOL. 12 ‧ NO. 4
Diabetes Breakthrough Treatment for Cardiovascular Diseases and Beyond	FEBRUARY 2020 ‧ VOL. 12 ‧ NO. 2
The Story of Statins	NOVEMBER 2019 ‧ VOL. 11 ‧ NO. 8
Treatment of Non-alcoholic Fatty Liver Disease: Present and Future	OCTOBER 2019 ‧ VOL. 11 ‧ NO. 7
More Sweat, Less Sweet: How an Exercise Programme Made Positive Changes for an Obese Patient with Type 2 Diabetes	OCTOBER 2019 ‧ VOL. 11 ‧ NO. 7
Management of Type 2 Diabetes Mellitus in Obese Patients	OCTOBER 2019 ‧ VOL. 11 ‧ NO. 7
Update on Medical Treatment of Obesity	OCTOBER 2019 ‧ VOL. 11 ‧ NO. 7
New Classes of Diabetes Mellitus Drugs: From Insulin to Non-insulin	JULY 2019 ‧ VOL. 11 ‧ NO. 5
Familial Hypercholesterolaemia - Finding the Needle in the Haystack	JULY 2019 ‧ VOL. 11 ‧ NO. 5
New Challenges in Endocrinology - Immunotherapy-Related Endocrinopathies	APRIL 2019 ‧ VOL. 11 ‧ NO. 3
Advances in Scarless Management of Benign Thyroid Nodule: From Ablation to Resection	APRIL 2019 ‧ VOL. 11 ‧ NO. 3
Diabetic Eye Diseases	APRIL 2019 ‧ VOL. 11 ‧ NO. 3
Updates on New Strategies and Pharmacological Weapons Against Type 2 Diabetes Mellitus	APRIL 2019 ‧ VOL. 11 ‧ NO. 3
Food Supplements and Cholesterol/Cardiovascular Health	NOVEMBER 2018 ‧ VOL. 10 ‧ NO. 7
Reducing LDL Cholesterol to Prevent Atherosclerotic Cardiovascular Disease	AUGUST 2018 ‧ VOL. 10 ‧ NO. 5
COPD with Comorbid Diabetes Mellitus	MAY 2018 ‧ VOL. 10 ‧ NO. 4
The More I Know, The More I Know That I Don't Know	APRIL 2018 ‧ VOL. 10 ‧ NO. 3
What's Next After Metformin? How to Choose the Second Anti-Diabetic Drug in a Primary Care Setting	APRIL 2018 ‧ VOL. 10 ‧ NO. 3
Advancements in Obesity Medicine in the Past Decade	APRIL 2018 ‧ VOL. 10 ‧ NO. 3
Screening and Management of Diabetic Nephropathy	APRIL 2018 ‧ VOL. 10 ‧ NO. 3
Coronary Artery Disease Screening in Patients with Type 2 Diabetes	APRIL 2018 ‧ VOL. 10 ‧ NO. 3
Metabolic Syndrome and Perspectives for Future Research: A Brief Review	JANUARY 2018 ‧ VOL. 10 ‧ NO. 1
Latest Insights on the Treatment of Dyslipidemia	NOVEMBER 2017 ‧ VOL. 9 ‧ NO. 7
Recent Advances in the Management of Type 2 Diabetes	NOVEMBER 2017 ‧ VOL. 9 ‧ NO. 7
Clinical Benefits of the Potent Antioxidant Probucol	NOVEMBER 2017 ‧ VOL. 9 ‧ NO. 7
Insulin Initiation in Patients with Type 2 Diabetes	JULY 2017 ‧ VOL. 9 ‧ NO. 5
Comorbidities of Gout	APRIL 2017 ‧ VOL. 9 ‧ NO. 3
SGLT2 Inhibitors: A New Class of Antidiabetic Drugs	NOVEMBER 2016 ‧ VOL. 8 ‧ NO. 7
Oxidative Stress and Inflammation in Atherosclerosis	NOVEMBER 2016 ‧ VOL. 8 ‧ NO. 7
SGLT2 Inhibitors: A New Class of Antidiabetic Drugs	SEPTEMBER 2016 ‧ VOL. 8 ‧ NO. 6
Management of Obesity in Patients with Type 2 Diabetes	SEPTEMBER 2016 ‧ VOL. 8 ‧ NO. 6
The Important Role of Diet in the Management of Hypercholesterolemia and Prevention of Coronary Heart Disease	JULY 2016 ‧ VOL. 8 ‧ NO. 5
Gout: What is the Treatment Target and How to Achieve the Target?	FEBRUARY 2016 ‧ VOL. 8 ‧ NO. 2
Pharmacogenomics: The Promises of Personalized Medicine	JANUARY 2016 ‧ VOL. 8 ‧ NO. 1
The Impact of GLP-1 Receptor Agonists on Weight in Obese Patients with Type 2 Diabetes Mellitus	DECEMBER 2015 ‧ VOL. 7 ‧ NO. 7
Role of Probucol in the Current Treatment of Atherosclerosis and Vascular Disease	NOVEMBER 2015 ‧ VOL. 7 ‧ NO. 6
2015 Update in Diabetes, Endocrinology & Metabolism	NOVEMBER 2015 ‧ VOL. 7 ‧ NO. 6
Probucol: Reappraisal of an Old Drug for Atherosclerosis	MAY 2015 ‧ VOL. 7 ‧ NO. 3
Year of Endocrinology, Diabetes & Metabolism 2014	NOVEMBER 2014 ‧ VOL. 6 ‧ NO. 6
Update on the Use of Angiotensin Receptor Blockers in Hypertension: A Focus on Azilsartan Medoxomil	JUNE 2014 ‧ VOL. 6 ‧ NO. 3
Update on Gout Management	DECEMBER 2013 ‧ VOL. 5 ‧ NO. 7
Type 2 Diabetes and Comorbidities: The Management Challenges	DECEMBER 2013 ‧ VOL. 5 ‧ NO. 7
Blood Pressure Variability: Is It Important and How Can We Assess It?	DECEMBER 2013 ‧ VOL. 5 ‧ NO. 7
Glucocorticoid-Induced Osteoporosis - Who Should be Treated	MAY 2013 ‧ VOL. 5 ‧ NO. 3
Heart Rate Reduction as a Goal in the Management of Cardiovascular Risk	MARCH 2013 ‧ VOL. 5 ‧ NO. 2
Role of Bone Mineral Density in Fracture Risk Assessment	MARCH 2013 ‧ VOL. 5 ‧ NO. 2
Update on Management of Gout and Hyperuricaemia	JANUARY 2013 ‧ VOL. 5 ‧ NO. 1
New Directions in Management Type 2 Diabetes Mellitus	DECEMBER 2012 ‧ VOL. 4 ‧ No. 7
The Role of Combination Therapy in the Management of Hypertension	MAY 2012 ‧ VOL. 4 ‧ NO. 3
Update in Oral Antidiabetic Drugs in Type 2 Diabetes	DECEMBER 2011 ‧ VOL. 3 ‧ NO. 7
Niacin for the Treatment of Dyslipidaemia and Atherosclerosis	JULY 2011 ‧ VOL. 3 ‧ NO. 4
Atypical Femoral Fractures and Bisphosphonates: New Aspects	MAY 2011 ‧ VOL. 3 ‧ NO. 3
New Treatment Modalities in Osteoporosis	MARCH 2011 ‧ VOL. 3 ‧ NO. 2
Recent Advances in Therapeutics in Osteoporosis	JANUARY 2011 ‧ VOL. 3 ‧ NO. 1
The Role of thiazolidinediones in the Management of Type 2 Diabetes	DECEMBER 2010 ‧ VOL. 2 ‧ NO. 8
Increase in Bone Mineral Density During Testosterone Therapy in Chinese Hypogonadal Men	MAY 2010 ‧ VOL. 2 ‧ NO. 3
Differential Diagnosis of Hypercalcaemia	APRIL 2009 ‧ VOL. 1 ‧ NO. 2